Candidaemia in adult cancer patients: Risks for fluconazole-resistant isolates and death

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 5, 2010, Pages 1042-1051

  Slavin, Monica A ^a   Sorrell, Tania C ^b   Marriott, Deborah ^c   Thursky, Karin A ^a   Nguyen, Quoc ^c   Ellis, David H ^d   Morrissey, C Orla ^e   Chen, Sharon C A ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^e ALFRED HOSPITAL   (Australia)

Author keywords

Candida; Mortality; Susceptibility; Triazoles

Indexed keywords

AMPHOTERICIN B; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CORTICOSTEROID; CREATININE; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM ISOLATE; CANCER PATIENT; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDEMIA; COMORBIDITY; DEVICE REMOVAL; FEMALE; GASTROINTESTINAL SURGERY; HEMATOLOGIC MALIGNANCY; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; RISK FACTOR; SOLID TUMOR; TREATMENT OUTCOME; ANTIFUNGAL RESISTANCE; CANDIDA; CANDIDIASIS; CLASSIFICATION; DRUG EFFECT; FUNGEMIA; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; NEOPLASM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOLOGICAL TYPING TECHNIQUES; NEOPLASMS; RISK FACTORS; YOUNG ADULT;

EID: 77953721388     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq053     Document Type: Article

References (36)

1. Tortorano AM, Kibbler C, Penman J et al. Candidemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006; 27: 359-66.
2. Wey SB, Mori M, Pfaller MA et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642-5.
3. Zaoutis TE, Argon J, Chu J et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-9.
4. Sipsas N, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007). Cancer 2009; 115: 4745-52.
5. Hachem R, Hanna H, Kontoyiannis D et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112: 2493-9.
6. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
7. Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-61.
8. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
9. Antoniadou A, Torres HA, Lewis RE et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003; 82: 309-21.
10. Sabino R, Verissimo C, Brandao J et al. Epidemiology of candidemia in oncology patients: a 6-year survey in a Portuguese central hospital. Med Mycol 2009; 5: 1-10.
11. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
12. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
13. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007; 51: 35-9.
14. Baddley JW, Patel M, Bhavnani SM et al. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008; 52: 3022-8.
15. Riddell JT, Kauffman CA. The evolution of resistant Candida species in cancer centers: implications for treatment and prophylaxis. Cancer 2008; 112: 2334-7.
16. Chen S, Slavin M, Nguyen Q et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006; 12: 1508-16.
17. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-6.
18. International Statistical Classification of Disease and Related Health Problems, 10th Revision, Australian Modification (ICD-10-AM). Sydney, Australia: University of Sydney, 1998.
19. Warren N, Hazen K. Candida, Cryptococcus, and other yeasts of medical importance. In: Murray PR, Baron EJ, Pfaller MA et al., eds. Manual of Clinical Microbiology. Washington, DC: ASM Press, 1999; 1184-99.
20. Kurtzman CP, Fell JW. The Yeasts, A Taxonomic Study. 4th edn. Amsterdam, The Netherlands: Elsevier Science B.V., 1998.
21. Meyer W, Maszewska K, Sorrell TC. PCR fingerprinting: a convenient molecular tool to distinguish between Candida dubliniensis and Candida albicans. Med Mycol 2001; 39: 185-93.
22. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts- Second Edition. Approved Standard M27-A2. NCCLS,Wayne, PA, USA, 2002.
23. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution and Antifungal Susceptibility Testing of Yeasts: Third Informational Supplement M27-S3. CLSI, Wayne, PA, USA, 2008.
24. Almirante B, Rodriguez D, Park BJ et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-35.
25. Playford EG, Marriott D, Nguyen Q et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008; 36: 2034-9.
26. Komshian SV, Uwaydah AK, Sobel JD et al. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989; 11: 379-90.
27. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
28. Thursky KA, Playford EG, Seymour JF et al. Recommendations for the treatment of established fungal infections. Intern Med J 2008; 38: 496-520.
29. Herbrecht R, Fluckiger U, Gachot B et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. EJC Supplements 2007; S5: 49-50.
30. Hope WW, Drusano GL, Moore CB et al. Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. Antimicrob Agents Chemother 2007; 51: 285-95.
31. Velasco E, Bigni R. A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis 2008; 27: 1071-8.
32. Anaissie EJ, Rex JH, UzunOet al. Predictors of adverse outcomein cancer patients with candidemia. Am J Med 1998; 104: 238-45.
33. Vigouroux S, Morin O, Moreau P et al. Candidemia in patients with hematologic malignancies: analysis of 7 years' experience in a single center. Haematologica 2006; 91: 717-8.
34. Liu CY, Huang LJ, Wang WS et al. Candidemia in cancer patients: impact of early removal of non-tunnelled central venous catheters on outcome. J Infect 2009; 58: 154-60.
35. Silva S, Henriques M, Martins A et al. Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition. Med Mycol 2009; 47: 681-9.
36. Knaus WA, Draper EA, Wagner DP et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.